NCT00704808View on ClinicalTrials.gov

Post Marketing Surveillance: Newly Diagnosed Glioblastoma Multiforme Treated With Radiotherapy/Temozolomide and Adjuvant Temozolomide (Study P04739)

CompletedOBSERVATIONAL
Enrollment

180

Participants

Timeline

Start Date

May 31, 2006

Primary Completion Date

December 31, 2008

Study Completion Date

December 31, 2008

Conditions
Glioblastoma
Interventions
PROCEDURE

Primary surgical treatment

Primary surgery for tumor resection.

RADIATION

Radiotherapy

Radiotherapy is given with concomitant temozolomide. Dosing according to European Summary of Product Characteristics.

DRUG

Temozolomide

Temozolomide is first given with concomitant radiotherapy, and then as monotherapy (adjuvant chemotherapy). Dosing according to European Summary of Product Characteristics.

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT00704808 - Post Marketing Surveillance: Newly Diagnosed Glioblastoma Multiforme Treated With Radiotherapy/Temozolomide and Adjuvant Temozolomide (Study P04739) | Biotech Hunter | Biotech Hunter